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THERMAL PROPERTIES AND EUTECTIC BEHAVIOUR OF DAPIVIRINE IN 
COMBINATION WITH STEROID HORMONES AND OTHER ANTIRETROVIRALS
Karl Malcolm 1, Clare McCoy 1, Diarmaid Murphy 1 , Peter Boyd 1, Sandeep Kumar 1, Susan Fetherston 1 ,
Andrew Brimer 2, Jonathon Holt 2, Brid Devlin 2 , Wendy Blanda 2, Jeremy Nuttall 2, Chris Gilmour 2
1 Queen’s University Belfast, UK, 2 International Partnership for Microbicides (IPM), USA.
It is well established that the melting point of a drug is inversely proportional to its lipophilicity [e.g. 
Calpena et al., J Pharm Sci, 83 (1994) 29–33] which, in turn, correlates with its ability to be absorbed in 
vivo. Therefore, if the melting point of a drug can be reduced without affecting other physicochemical 
parameters, then drug release and/or absorption may be enhanced. This general principle has been 
exploited in a number of marketed pharmaceutical products, including the topical anaesthetic cream 
EMLA™ and the contraceptive vaginal ring Nuvaring®. Both products contain two active pharmaceutical 
ingredients – EMLA™ contains a mixture of prilocaine and lidocaine, while Nuvaring® contains 
etonogestrel and ethinyl estradiol (Fig. 1). Each drug in these combinations serves to reduce the melting 
point of the other drug, much in the same way that salt reduces the melting point of water (explaining its 
use on icy roads). For example, the phase diagram for etonogestrel and ethinyl estradiol shows that the 
maximum reduction in drug melting point occurs for a 1:1 mixture (Fig. 2).    
Figure 1. 
Examples 
of combination 
drug products 
formulated as 
eutectic mixtures.
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Fig. 2. Phase diagram of etonogestrel and ethinyl estradiol.
ished (i.e. shifted towards the solid phase) and so
the equilibrium of the system will be reestablished.
Eq. (5) can also be used to describe the eutectic
behavior of steroid mixtures (Dorset, 1988, 1992).
In order to calculate the eutectic behavior of the
steroids investigated in this report, Eq. (9) was
deducted from Eq. (5). Because the solubility
parameters of the steroids investigated are almost
equal (Table 1), the second term in Eq. (5) will be
zero.
T(A)=
−
 1
(log(1−X(B)) (2.303R/Hf(A)))−1/T0(A)
n
, (9)
where T(A) is decreased melting point of steroid A
(K); Hf(A), heat of fusion steroid A (J/mole);
T0(A), melting point of steroid A (K); R, gas law
constant (8.314 J/mole K); X(B), molar fraction
steroid B.
In Fig. 2, Eq. (9) is used to calculate the
melting point depression between etonogestrel
and ethinyl estradiol. Because the equation is
meant for ideal solutions, the calculated melting
point depression does not fit perfectly. Most im-
portant, however, is to realize that the lower
melting point T(A) will result in a higher solubility
in the polymer (Eq. (5)). Hence, the solubility of
etonogestrel is raised in the presence of ethinyl
estradiol because of the eutectic melting point
depression.
4.1.3. Time– lag method
The amount of steroid measured in the acceptor
cell has been plotted against time. The permeabil-
ity and diffusion coefficients were calculated from
the slope and intercept of the curve, using Eqs. (7)
and (8). The maximal saturation of the membrane
(Cs) was calculated from the permeability and the
diffusion coefficient.
It was found that the solubility and diffusion
coefficient of etonogestrel in EVA 9 was, respec-
tively 0.055 wt.% and 1.84×10−9 cm2/s. The
solubility found with the time– lag method is al-
most equal to the value found with the saturation
experiments in flat films (0.058 wt.%).
4.2. Formulation studies
4.2.1. The influence of the steroid concentration
on the release
In Fig. 3 the release of coaxial fibers with
varying concentrations of etonogestrel in the core
has been plotted. In the first few days a higher
release rate can be observed. This so-called burst
release is caused by release of the steroid from the
membrane polymer.
Figure 2. Phase diagram for 
etonogestrel and ethinyl estradiol, 
the drug components of Nuvaring [Van 
Laarhoven et al., Int J Pharm, 232 (2002) 
163–173]. 
Combination microbicide and multi-
purpose prevention technology 
(MPT) products in which the active 
pharmaceutical ingredients are intimately 
associated may also offer increased drug 
release / absorption on account of reduced 
melting behaviour. Here, we report that the lead antiretroviral microbicide candidate dapivirine (DPV) 
consistently forms eutectic or reduced melting temperatur  compos tions with various antiretrovirals 
and steroid hormones that might be included as part of a MPT product.      
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A Figure 5. Phase 
diagrams for various 
dapivirine combinations. 
A – levonorgestrel (LNG), 
B – maraviroc (MVC), 
C – darunavir (DRV), D 
– 17 beta-estradiol (E2). 
According to figures E–H, 
the eutectic or lowest 
melting composition 
is determined as the 
composition having the 
largest heat of fusion value 
for the eutectic melting 
transition. These eutectic 
compositions are indicated 
by a dashed line.
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Figure 4. DSC traces showing thermal 
behaviour of DPV and LNG mixtures. 
DPV shows a polymorphic transition at 105°C 
and a melting endotherm at 220°C. All other 
combinations showed similar thermal behaviour.
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Figure 3. DSC thermogram showing 
thermal behaviour of DPV alone. 
During the first heating cycle, DPV shows a 
polymorphic transition at 105°C and a crystalline 
melt at 222°C. Following cooling, a second 
heat cycle shows a glass transition at 80°C, 
a recrystallisation process at 160°C and a 
subsequent crystalline melt at 220°C.  
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